Key facts
- This page summarizes H. Paul Dorman's Form 4 filing for Phio Pharmaceuticals Corp. (PHIO).
- 1 reported transaction and 0 derivative rows are listed below.
- Accepted by SEC: 16 Feb 2022, 19:05.
H. Paul Dorman - 15 Feb 2022 Form 4 Insider Report for Phio Pharmaceuticals Corp. (PHIO)
- Reporting relationship
- Director
- Issuer ticker
- PHIO
- Reported as of
- 15 Feb 2022
- Net transaction value
- $0
- Reporting owner signature
- Caitlin Kontulis, attorney-in-fact
Source evidence
Original filing metadata and source links for verification.
3 source fields
Reporting owner
1 detail
Key filing fact
H. Paul Dorman filed Form 4 for Phio Pharmaceuticals Corp. (PHIO) on 16 Feb 2022.
Change
- No earlier filing in this sequence is available for direct comparison.
- Current net transaction value: $0.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
PHIO
transaction
Common stock, $0.0001 par value
Award
- Transaction value
- $0
- Shares
- +10,000
- Change %
- +96%
- Price
- $0.000000
- Shares after
- 20,370
- Date
- 15 Feb 2022
- Ownership
- Direct
- Footnotes
- F1, F2
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 2 footnotes
Footnote F1
Represents shares underlying a restricted stock unit, which shares will vest in one installment on the first anniversary of the grant date.
Footnote F2
Includes shares of common stock underlying unvested restricted stock units.